Kim et al.56 reported that a difference in sensitivity to FGFR2 inhibitor of AZD4547 may be related to baseline FGFR2 IIIC expression level caused by tumor heterogeneity using patient-derived tumor cell models. The gene discussed is FGFR2; the disease is neoplasm.